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Abstract: Thyroid cancer, a cancerous tumor or growth located within the thyroid gland, is the most
common endocrine cancer. It is one of the few cancers whereby incidence rates have increased in
recent years. It occurs in all age groups, from children through to seniors. Most studies are focused
on dissecting its genetic basis, since our current knowledge of the genetic background of the different
forms of thyroid cancer is far from complete, which poses a challenge for diagnosis and prognosis
of the disease. In this review, we describe prevailing advances and update our understanding of
the molecular genetics of thyroid cancer, focusing on the main genes related with the pathology,
including the different noncoding RNAs associated with the disease.
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1. Introduction
Thyroid cancer is the most common endocrine cancer, with an increasing overall incidence in recent
decades of about two fold in the last 25 years and accounting for 2% of all cancers [1]. Thyroid cancer
is the sixth most common cancer in women, who are three times more likely to have thyroid cancer
than men. About 2% of cases occur in children and teens. Overall, the 5-year survival rate of thyroid
cancer is 98%. However, survival rates depend on many factors, such as the specific type of thyroid
cancer and stage of disease [2]
Several types and histological subtypes can be found depending on the cells from which the tumor
derives, and each one presents different characteristics and prognoses. Non-medullary thyroid cancer
(NMTC) originates from follicular cells and is responsible for ~95% of all the cases. At the same time,
NMTC is divided into four groups (also known as well differentiated thyroid cancer): (1) papillary
thyroid cancer (PTC), which represents more than 85% of cases, (2) follicular thyroid cancer (FTC; 10%
of total cases), (3) poorly differentiated thyroid cancer (PDTC, which accounts for only 1–15% of all
thyroid cancers), constitutes a more aggressive follicular-derived thyroid cancer than differentiated
thyroid cancer (PTC and FTC), and (4) anaplastic cancer (ATC) (<1%) [3].
Of the total number of cases, 10% of NMTCs occur during the first two decades of life [4].
Around 5% present as familial forms and the remaining 95% are sporadic. Analysis (genome-wide
association study or genome-wide linkage analysis) has led to the identification of some genes
associated with non-syndromic familial forms, although additional populations are needed for further
validations [5–9]. In either case, the studies carried out to date are quite inconclusive, and thus new
approaches should be carried out for the identification of new loci associated with FNMTC.
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In addition, only ~5% of cases of thyroid cancer are derived from parafollicular cells and this
type is named medullary thyroid cancer (MTC) [4,10]. About 75% of all MTCs are believed to
be sporadic (sMTC), and the remaining 25% correspond to inherited cancer syndromes known as
multiple endocrine neoplasia type 2 (MEN2). MEN2 includes three clinically differentiable types:
MEN2A (OMIM #171400), MEN2B (OMIM #162300), and FMTC (OMIM #155240; which may be a
variant of MEN 2A) [11,12]. FNMTC is a rare form of thyroid cancer (only 3–9% of all cases). Moreover,
just 5% of the family forms are included in specific syndromes: Cowden (OMIM #158350), Gardner
(OMIM #175100), Werner (OMIM #277700), Li-Fraumeni (OMIM #151623), McCune-Albright (OMIM
#174800), Carney complex (OMIM #160980), or DICER 1 (OMIM #138800) syndromes [5,6]). This review
summarizes the current knowledge about molecular bases of thyroid cancer: from genes to ncRNAs,
to provide the reader an overview of the main genetic and epigenetic factors that can influence the
develop of thyroid cancer.
2. Molecular Genetics of Thyroid Cancer
Alterations on some genes and pathways have been described to be associated with the
different forms of thyroid cancer. The most relevant are summarized in the current review
(Figure 1). Thyroid tumorigenesis and progression are closely linked to somatic point mutations
on BRAF (B-rapidly accelerated fibrosarcoma), RAS, RET, and NTRK1/3 genes that promote the
activation of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling
pathways [13,14]. Interestingly, there is a strong relationship between the oncogenic genotype and
histopathologic phenotype, mutations in BRAF, PAX8, and PPARG genes being common in FTC and
RASmutations either in FTC and PTC (follicular variant, fvPTC) [15–19]. The global analysis of genomic
variants, gene and miRNA expression, aberrant methylation, and proteomic profiles unraveled that
mutations in BRAF and RAS, together with RET-PTC fusions, are the most common genetic alterations
in both FTC and PTC.
It is worth mentioning The Cancer Genome Atlas (TCGA) project outcomes, where a comprehensive
and multiplatform approach to analyze multidimensional molecular data of 496 PTCs (excluding both
poorly and undifferentiated carcinomas to compile all tumor-initiating alterations) was performed.
Such a cohort led to classification into molecular subtypes (including tumor cluster, histology, genotype,
signaling, and risk assessment) to associate them with clinically relevant parameters and improve the
management of patients. They mainly distinguish two types of PTC tumors: PTCs with RAS mutations
(RL-PTCs) and BRAFV600E-driven tumors (BVL-PTCs). Both are basically different in their genomic,
epigenomic, and proteomic profiles, which is in concordance with their histological differences [20].
3. The RET Proto-Oncogene Role
In 1993 RET proto-oncogene was demonstrated to be the causative event for MTC [21]. Since then,
several mutations have been described in MEN2 series. Thus, the RET genetic screening is a crucial
diagnostic and prognostic procedure for MTC [22].
3.1. Somatic RET Mutations
3.1.1. RET Gene Rearrangements
The Rearranged During Transfection (RET) gene encodes a single transmembrane receptor, which
is a tyrosine kinase implicated in the cellular signaling of members of the glial derived neurotrophic
factors family [23].
In PTC, RET rearrangements (RET-PTC) seem to be an early event in carcinogenesis, with 10–20%
of RET fusions being detected in PTC patients. RET-PTC fusions used to be associated with sporadic
and radiation-induced PTC [24,25]. In addition, coiled-coil domain containing 6-RET rearrangements are
also commonly found in this type of tumor [26,27]. The presence or higher expression of a RET fusion
protein has been linked to regional invasion and lymph node metastasis [28].
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Figure 1. Progression of thyroid cancer and the main genetic alterations involved in such process. (A) Picture depicting thyroid cancer hystotypes and their causative
genetic events. PTCs present BRAF (V600E substitution), RAS mutations, and/or RET/PTC rearrangements. FTCs display PPARc/Pax8 rearrangements, RAS mutations,
and PTEN inactivating mutations or deletions. ATCs are characterized by PTEN and CTNNB1 mutations and p53 inactivation. (B) Schema shows the key molecular
signaling pathways involved in thyroid cancer. On the left (inside the circle with dashed blue line): MAPK pathway, which is activated in most thyroid cancers
after a mutational event. Once thyroid cancer development is initiated, gene expression is altered, evoking cell proliferation, cell growth, angiogenesis, and loss of
differentiation. On the right (inside the circle with dashed red line): pathways altered in advanced thyroid cancers, which promote tumor progression. This includes
the PI3K–mTOR pathway, the p53 tumor suppressor, and alterations in the promoter for TERT. miRNAs, lncRNAs and circRNAs are also represented inside the
nucleus as genetic players in thyroid cancer development.
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Thus, RET rearrangements are determinant on the evaluation of thyroid nodules with undefined
cytology. The main RET/PTC oncoproteins are summarized in Table 1.
Table 1. RET/PTC oncoproteins related with thyroid cancer.
RET/PTC
Rearrangement Fusion Partner
Chromosomal
Alteration Reference
RET/PTC1 Coiled-coil domain-containing protein 6 (CCDC6) inv10(q11.2;q21) [29]
RET/PTC2 Protein kinase, cAMP-dependent, regulatory, type I,alpha (PRKAR1A) t(10;17)(q11.2;q23) [30]
RET/PTC3 Nuclear coactivator 4 (RET-fused gene, androgenreceptor-associated protein 70) (NCoa4 (RFG, ARA70) inv10(q11.2;q10) [29]
RET/PTC4 Nuclear coactivator 4 (RET-fused gene, androgenreceptor-associated protein 70) (NCoa4 (RFG, ARA70) inv10(q11.2;q10) [31]
RET/PTC5 RET-fused gene 5 (Golgin A5) (RFG5 (GOLGA5)) t(10;14)(q11.2;q32) [32]
RET/PTC6 Tripartite motif-containing 24 (TRIM24) t(7;10)(q32-q34;q11.2) [33]
RET/PTC7 RET-fused gene 7 (tripartite motif-containing 33(RFG7(TRIM33)) t(1;10)(p13;q11.2) [33]
RET/PTC8 Kinectin 1 (KTN1) t(10;14)(q11.2;q22.1) [34]
RET/PTC9 RET-fused gene 9 (RFG9) t(10;18) (q11.2;q21-22) [35]
RET/ELKS Glutamate, leucine, lysine, serine-rich sequence(RAB6-interacting protein 2) (ELKS (RAB6IP2)) t(10;12)(q11.2;p13.3) [36]
RET/PCM1 Pericentriolar material 1 (PCM1) t(8;10)(q21-22;q11.2) [37]
RET/RFP RET finger protein (tripartite motif-containing 27)(RFP (TRIM27)) t(6;10)(p21;q11.2) [38]
RET/HOOK3 Hook homolog 3 (HOOK3) t(8;10)(p11.21;q11.2) [39]
Most relevant genes in thyroid cancer: a compilation of the main genes related with the disease, indicating their
location, their main type of alterations (somatic or germline mutations), and their incidence on the disease. A footnote
with the main databases available to access all RET variants “with clinical relevance to date”, indicating their number
registered on each database until the last access, is included.
3.1.2. Other Somatic RET Mutations
The genetic bases for nearly all thyroid cancers have been solved through DNA sequencing
studies. Most thyroid tumors harbor mutations that eventually activate MAPK and PI3K-AKT signaling
pathways, which regulate cellular proliferation [3,40,41]. Furthermore, somatic RET mutations appear
in 40–50% of sporadic MTCs and have been linked with a worse prognosis for patients. In fact, the
presence of a somatic RET mutation is associated with lymph node metastases at diagnosis, which is
a bad prognostic factor for complete cure for such patients [22]. Somatic RET mutations have been
described in sporadic cases of MTC [42] as well as loss of heterozygosity at different loci (deletions of
tumor suppressor genes) in MTC [21]. In addition, a mutation in codon 664 of the RET gene, which
affects the protein kinase domain of the gene product by changing a threonine for a methionine, was
found in unrelated MEN2B patients as well as in six sporadic tumors [43].
The application of new approaches has improved the knowledge of somatic RET mutations such
as RETM918T mutation. A genome-wide DNA methylation profiling was performed in a large MTC
series. Integration of methylation data together with mRNA and miRNA expression data revealed
JAK/Stat signaling effector STAT3 as a potential therapeutic target for these tumors [44].
3.2. Germline RET Mutations
Gain-of-function RET mutations give rise to MEN2 [23,45]. In MEN2, mutations in the RET
intracellular domains lead to activation of RET monomers while in the extracellular domain carry to
dimerization [23,46]. Thus, MEN2 RET receptors constitutively activate signaling pathways linked to
wildtype RET activity [47,48]. In fact, MEN2 phenotype is more severe when specific RET mutations
lead to increased kinase activity [49,50]. Based on these observations, the clinical management
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guidelines for MEN2 patients recommend early genetic screening in at-risk individuals, in order
to determine if they carry any RET mutation, which is associated with the poorest prognosis [50].
There are three American Thyroid Association categories: I) moderate-risk mutations (exon 10, exon 11
mutations other than codon 634, and exons 13 through 15), which lead to relatively late MTC onset; II)
high-risk mutations (exon 11, codon 634, the classical MEN2A mutation; and exon 15, codon 883), which
present intermediate risk; and III) highest-risk mutations, with the typical MEN2B mutation (exon 16,
codon 918), which confer the highest risk of early MTC development and growth [51]. All updated
information regarding the effect of RET mutations on sporadic and familial cases of thyroid cancer is
compiled in different reviews [26,52,53].
More than 95% of MEN2 cases have germline mutations in the RET proto-oncogene, leading to a
constitutive activation of the metabolic pathways of RET signaling [54]. Of those patients, 98% have
mutations grouped in a hotspot composed of five cysteine codons present in the extracellular domain of
the protein (C609, C611, C618, C620, C630, C634) [49,55,56]. Eighty-seven percent of MEN2A patients
carry mutations affecting codon 634, C634R being the most prevalent one that has been detected [49],
unlike in the Spanish population, who mostly carry the C634Y mutation [57–60]. In addition, although
over 70 RET mutations have been described in MEN2A patients (all in the extracellular region, close to
the transmembrane domain), only two RET mutations (affecting codons 918 and 883) have been linked
to MEN2B [61].
Regarding FMTC missense mutations in the tyrosine kinase domain, one changes glutamate 768
for an aspartate and another one substitutes valine 804 for a leucine. In addition, there are some relevant
mutations on cysteine codons and the transmembrane domain, some of them shared with MEN2A
syndrome, which are updated and summarized in Figure 2. Both are gain-of-function mutations and
result in aberrant signaling mediated by RET [42,62,63].
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Figure 2. Schematic structure of RET, and mutations identified in MEN2A, MEN 2B and familial medullary thyroid carcinoma (FMTC). Modified from [64,65].
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3.3. Susceptibility Factors
A germline RET S836S variant (c.2508C>T, rs1800862) has been correlated with somatic RETM918T
mutation in exon 16, which leads to a more aggressive sMTC. Furthermore, this variant was found to
have a significantly higher frequency in sMTC compared to controls, which led to it being considered as
the first genetic susceptibility factor for the disease [64,66–68]. Additionally, IVS1-126G>T (c.74-126G>T,
rs2565206) and G691S (c.2071G>A, rs1799939, p.Gly691Ser)/S904S (c.2712C>G, rs1800863) have also
been described as associated with sMTC in several populations although this finding was not replicated
in a larger study [69]. The RET c*587T>C variant was restricted to the Italian population [70–73].
It has been suggested that variants in genes encoding for RET coreceptors might play a role in the
pathogenesis of sMTC. A study of the German population showed that GFRA1-193C>G and c.537T>C
were overrepresented in sMTC versus controls, which suggested that both variants could be in linkage
disequilibrium with other locus responsible for the disease. However, such overrepresentation was
not found in a similar study of the Spanish population, supporting a founder effect of both variants in
Germany [74].
4. BRAF
The most frequent mutations (60%) in PTC patients are found on the BRAF gene. Moreover, the
BRAFV600E mutation (p.Val600Glu; commonly known as V600E), which is found in 95% of cases, is
used as a risk biomarker in PTC [20]. Although somatic mutations in this gene are absent on benign
thyroid nodules, they appear on a third of anaplastic thyroid cancers [75,76]. As we mentioned above,
the majority of BRAF mutations implicate the activation of the kinase domain of this protein, which
finally dysregulates the MAPK signaling pathway [77–79], thus being relevant in cellular processes
implicated in cancer development such as tumorigenesis, proliferation, and progression [80,81].
5. RAS
The RAS genes (H-RAS, N-RAS, K-RAS) present somatic point mutations in follicular adenoma,
FTC (40–53%), PTC (0–20%), fvPTC (17–25%), and poorly differentiated and anaplastic thyroid cancer
(20–60%) [19,75,82–85]. A codon 61 mutation of NRAS (N2) was identified four times more frequently
in follicular tumors than in papillary cancers, and it is the second most common point mutation with
an incidence of 8.5% [20]. Thus, RAS mutations are associated with follicular tumors that compile from
a preinvasive lesion to a true malignancy, either FTC, PTC, fvPTC, or poorly differentiated thyroid
cancer [84,86]. RAS mutations together with TERT promoter mutations (C228T and C250T) have been
associated with more aggressive and recurrent thyroid tumor and patient mortality, especially in PTC
patients. Although further studies are needed, these outcomes indicate that TERT is a new oncogene in
thyroid cancer and promoter mutations may be promising in clinical management of thyroid cancer,
especially in combination with BRAF V600E or RAS mutations [87].
6. PAX8-PPARG
The PAX8-PPARG fusion protein is the product of a t(2;3)(q13;p25) chromosomal translocation,
which used to be linked to FTC, and presents oncogenic capacity in transgenic mice [88].
PAX8-PPARG-positive tumors present a more prominent vascular and capsular invasion than
RAS-positive tumors [16].
7. Other Genes
In ATC the accumulation of several oncogenic alterations is equivalent to an increased level of
dedifferentiation and aggressiveness [89]. The role that P53 plays in thyroid carcinogenesis is well
known, but the role of the remaining P53 family members in thyroid cancer needs further studies.
Increasing evidence indicates that such family members favor the development of multiple thyroid
cancer variants, and in addition they are being used as therapeutical targets [90].
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Furthermore, there is a lack of knowledge of pathways specifically associated with each RET
mutation and with non-RET-mutated sporadic MTC. A transcriptional profile assay, together with
pathway enrichment analysis and gene ontology biological processes, revealed that PROM1 could be
necessary for the survival of tumoral cells in this tumor [91].
In addition, a novel constitutional frameshift c.948delT mutation (p.G318Afs*22) in ESR2 was
found to segregate with MTC (without any identifiable RET mutation) [92]. However, this mutation
was not found in other series of patients, such as FMTC cases [93].
Rearrangements involving the anaplastic lymphoma kinase (ALK) gene with the striatin (STRN)
gene have been described, which constitutively activate ALK kinase, inducing tumor formation in
nude mice. Such fusion may represent a therapeutic target for patients with highly aggressive types of
thyroid cancer [94]. Moreover, the ETV6-NTRK3 rearrangement, exclusively found in fvPTC, together
with STRN-ALK are recurrent and absent in benign lesions, which could be useful for the diagnosis of
thyroid nodules [95].
There is a thyroid specific transcription factor, FOXE1, which plays an essential role in thyroid
development. Among other functions, it recognizes sites in thyroglobulin and thyroperoxidase and it
also aids in maintaining cellular differentiation in the adult thyroid. Some genes increase its expression
(Adamts9, Cdh1, Duox2, and S100a4) in the absence of FOXE1, while Casp4, Creld2, Dusp5, Etv5, Hsp5a,
Nr4a2, and Tm4sf1 decrease [96]. FOXE1 has been associated with hypothyroidism and PTC [97].
A single nucleotide polymorphism in FOXE1 rs965513 which has been related with differentiated
thyroid cancers in Caucasian population [98]
A compilation of the main genes related with the disease, indicating their location, their main type
of alterations (somatic or germline mutations) and their incidence on the disease has been included in
Table 2.
Table 2. Most relevant genes in thyroid cancer.
Gene Chromosome(Chr) Type of Alteration
Origin of
Mutation Disease Reference
RET (*) Chr 10
RET/PTC
rearrangements Somatic PTC [26–28]
Point mutations
Somatic sporadic MTC [43,99]
Germline
MEN2A [OMIM# 171400]), MEN2B
[OMIM#162300]) and FMTC [OMIM#
155240])
[23,45]
BRAF Chr 7
V600E mutation
(p.Val600Glu) Somatic PTC [75,76]
Point mutations Somatic ATC
RAS (N-, K-, H-)
NRAS: Chr 1;
KRAS: Chr 12;
HRAS: Chr 11
Point mutations Somatic
follicular adenoma, FTC, PTC, fvPTC,
poorly differentiated and anaplastic
thyroid cancer
[19,75,82–85]
PTEN Chr 10
Insertions, deletions,
splice site mutations and
large deletions
Germline Cowden syndrome 1 (CWS1, [OMIM#158350] [100]
PIK3CA Chr 3 Point mutations
Somatic PTC [101]
Germline Cowden syndrome 5 (CWS5, [OMIM#615108]) [17]
AKT1 Chr 14 Point mutations Germline Cowden syndrome 6 (CWS6, [OMIM#615109] [102]
TERT Promoter Chr 5
Mutations with a
co-occurrence with either
BRAF or RAS mutations
Somatic ATC and advanced stages of FNMTC [103,104]
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Table 2. Cont.
Gene Chromosome(Chr) Type of Alteration
Origin of
Mutation Disease Reference
JAK3 Chr 19 Point mutations Somatic FTC [105]
TP53 Chr 17 Point mutations
Somatic ATC, PDTC [106,107]
Germline Li-Fraumeni syndrome (LFS, [OMIM#151623]) [108]
CHEK2 Chr 22 Deletions and pointmutations Germline
Li-Fraumeni syndrome 2 (LFS2,
[OMIM# 609265]) [109]
MET Chr 7 Point mutations Somatic MTC [110]
ALK Chr 2 Gene rearrangements Somatic PTC, PDTC and ATC [111]
APC Chr 5 Point mutations
Somatic PTC [112,113]
Germline Gardner syndrome [OMIM# 175100] [113,114]
CTNNB1 Chr 3 Point mutations Somatic PTC [115]
(*) Databases including the registered RET variants up to date (October 25th, 2019): LOVD (v.3.0 Build 21c):
https://databases.lovd.nl/shared/genes/RET. From the 146 RET variants reported, this database does not distinguish
which ones are linked to thyroid cancer. Then, in order to see the specific variants associated with thyroid
cancer, it is useful to visit https://databases.lovd.nl/shared/diseases#id=0&order=symbol%2CASC&search_name=
thyroid%20cancer&page_size=100&page=1. ClinVar: https://www.ncbi.nlm.nih.gov/clinvar/?term=RET%5Bgene%
5D+thyroid+cancer. There have been reported 813 RET variants linked to any form of thyroid cancer. HGMD:
http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RET. From the 395 registered RET mutations in this database, 133 of
them are associated to thyroid cancer.
In summary, the molecular pathogenesis of differentiated thyroid cancer, with specific signaling
pathways and activating point mutations, has been elucidated. When some of the specific genes mutate,
the tumor become into more aggressive and advanced thyroid cancer. Some of those events, include:
RAS mutations (25% in poorly differentiated thyroid cancers); activating mutations of PIK3CA; point
mutation p.V600E in BRAF; mutations in CTNNB1 (β-catenin) which is involved in Wnt signaling, and
in TP53 (a tumor suppressor), which may participate in de-differentiation of these tumors [116,117].
In addition, copy-number gains (found in proto-oncogenes) or oncogenic gene amplifications are mostly
found in poorly differentiated and anaplastic than in differentiated thyroid carcinomas, suggesting that
these genetic alterations play an important role in the progression and aggressiveness of thyroid cancer.
This is the case, for example, of the genes encoding receptor tyrosine kinases (RTKs) and P13K-AKT
pathway members, where an increased protein expression will activate these signaling pathways [118].
Regarding ALK gene, it was found in 9% of poorly differentiated thyroid cancers, 4% of ATC and 1%
of PTC [119]. While MAPK and P13K-AKT pathways are firstly involved in differentiated thyroid
carcinoma, when genetic alterations accumulate, both pathways get activated and an evolution of the
tumor occurs into poorly differentiated and ATC [14].
8. ncRNAs
The global analysis of genomic variants, gene and microRNA (miRNA) expression, aberrant
methylation, and proteomic profiles revealed that mutations in BRAF and RAS, together with RET-PTC
fusions, are the most common genetic alterations in both FTC and PTC. However, epigenetic modulators,
such as non-coding RNAs (ncRNAs), have recently emerged as helpful factors for both the diagnosis
and treatment of these thyroid carcinomas. Specifically, ncRNAs such as miRNAs, circular RNAs
(circRNAs), and long non-coding RNAS (lncRNAs) have been implicated in the modulation of gene
expression that regulates cellular processes such as cell differentiation, proliferation, cell cycle, apoptosis,
migration, and invasion [120–123]. Over the past four decades, thyroid cancer has emerged as a major
health issue. Thus, the identification of novel molecular therapeutic targets for prognosis and diagnosis
to advance in the overall management of this malignancy is really needed. Interestingly, ncRNAs have
been identified together with epistatic gene interactions in sMTC and juvenile PTC, which help to
understand the genetic architecture of complex diseases and support the relevance that these elements
have to explain carcinoma development and progression [124,125].
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8.1. miRNAs
In the last twenty years, dysregulation of miRNAs have been linked to thyroid dysfunction
and oncogenicity leading to this type of cancer [122,126]. MiRNAs are an important class of small
regulatory RNAs with a length of ~22 nt that regulate post-transcription gene silencing [127,128].
They regulate gene expression by partial complementarity pairing with mRNAs, promoting their
degradation or blocking translation. This gene regulation leads them to participate in many biological
processes [129,130]. When thyroid malignant transformation occurs by MAPK oncogenes, a significant
reduction of “tumor-suppressor” miRNAs and activation of oncogenic miRNAs take place [131].
The most relevant thyroid differentiation genes and transcription factors as predicted targets of
microRNAs have been summarized in Table 3. The role of specific miRNAs in thyroid carcinogenesis
is under intensive investigation, as new examples of miRNAs in cancer pathways are reported almost
daily. As an example of such complexity, TCGA analysis unravel the presence of six miRNA clusters in
PTC. Cluster 1 (RAS-mutated tumors and follicular variants) is enriched with the miRNAs miR-181
and miR-182, while BRAF tumors are contained in the rest of clusters (Clusters 2–6). Cluster 5 (with
high levels of miR-146b and miR-375, and low levels of miR-204) and Cluster 6 (enriched with miR-21
and low levels of miR-204), are associated with the less-differentiated tumors and a higher risk of
recurrence [132]. In summary, the upregulated miRNAs target factors that suppress pathway activation
(of the three main signaling pathways activated in thyroid cancer—MAPK, PI3K, and TGFβ), while
the downregulated miRNAs target factors activating such pathways. In this scenario, those three
pathways remain activated in thyroid cancer where miRNAs are functioning as crucial modulators of
pathway activity. Then, they can be considered as potential therapeutic targets.
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Table 3. Targets of microRNAs: different genes and transcription factors have been described as targets of miRNAs.
Target miRNA References
SLC5A5 (NIS) miR-10-5p miR-15-5p miR-16-5p miR-21-5p miR-24-3p miR-33-5p miR-129-3p miR-153 miR-195-5p miR-199-3p
[131,133–137]
miR-200-3p miR-212-35p miR-223-3p miR-383-5p miR-424 miR-429 miR455-3p miR-489-3p miR-590-5p
TG
miR-10-5p miR-18-5p miR-24-3p miR-25-3p miR-30-5p miR-32-5p miR-33-5p mR-92-3p miR-133a-3p miR-133b
miR-138-5p miR-140-3p miR-142-5p miR-145-5p miR-204-5p miR-211-5p miR-216-5p miR-338-3p
TPO miR-28-3p miR-99-5p miR-100-5p miR-132-3p miR-212-3p miR-212-5p miR-370-3p miR-543
TSHR miR-19-3p miR-33-5p miR-140-3p miR-181-5p miR-219-5p miR-382-3p miR-493-5p miR-506-5p miR-508-3p
SLC26A4 (Pendrin) miR-10-5p miR-17-5p miR-18-5p miR-19-3p miR-20-5p miR-26-5p miR-33-5p miR-96-5p miR-103-3p miR-107
miR-122-5p miR-129-5p miR-133a-3p miR-144-3p miR-148-3p miR-150-5p miR-181-5p miR-183-5p miR-200-3p miR-302
SLC16A2 (MCT8) miR-7-5p mR-9-5p miR-19-3p miR-22-3p miR-23-3p miR-24-3p miR-29-3p miR-31-5p miR-24-5p miR-138-5p
miR-143-3p miR-145-3p miR-150-5p miR-182-5p miR-191-5p miR-200-3p miR-338-3p miR-375 miR-365-3p miR-429
DUOX1
miR-34-5p mir-125-5p miR-134-5p miR-135-5p miR-151-3p miR-153-3p miR-199-3p miR-217 miR-324-5p miR-338-3p
miR-371-5p miR-376c-3p miR-448 miR-449-5p miR-491-5p miR-532-3p
DUOX2
miR-9-5p miR-15-5p miR-16-5p miR-18-5p miR-31-5p miR-34-5p miR-135-5p miR-140-5p miR-148-3p miR-150-5p
miR-152-3p miR-192-5p miR-195-5p miR-203a-3p miR-205-5p miR-223-3p miR-424-5p miR-455-3p miR-489-3p miR-497-5p
PAX8
let-7-5p miR-24-3p miR-34-5p miR-101-3p miR-122-5p miR-137 miR-138-5p miR-140-3p miR-146-3p miR-150-5p
miR-182-5p miR-212-5p miR-214-5p miR-221-3p miR-222-3p miR-302-3p miR-372-3p miR-373-3p miR-449-5p miR-520-3p
NKX2-1
let-7-5p miR-15-5p miR-16-5p miR-23-3p miR-24-3p miR-30-5p miR-129-5p miR-133a-3p miR-133b miR-138-5p
miR-150-5p miR-196-5p miR-199-5p miR-214-5p miR216-5p miR-223-3p miR-338-3p miR-365-3p miR-375 miR-424
FOXE1
let-7-5p miR-1 miR-10-5p miR-17-5p miR-20-5p miR-23-5p miR-98-5p miR-128-3p miR-129-5p miR-130-3p
miR-138-5p miR-140-3p miR-146-5p miR-155-5p miR-182-5p miR-190-5p miR-194-5p miR-302 miR-372-3p miR-373-3p
HOXB4 MiR-10a miR-10b miR-23a miR-218
TIMP3 miR-221/222
ZNFR3 miR-146b-5p
FN1 miR-16
ITGA2 miR-613
PTEN miR-21 miR-107 miR-146b miRs 221/222
AXIN2 hsa-miR-15a
TP53INP1 hsa-miR-20b hsa-miR-106a
TP53INP2 hsa-miR-20a
BCL2 hsa-miR-15a
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Table 3. Cont.
Target miRNA References
KAT2B hsa-miR-20a
PTEN miR-15a miR-19a miR-19b miR-21 miR-24 miR-107 miR-146b p miRs 221/222 miR-486-5p
KIT miRs 221/222
AKT3, ZNRF3, Smad4 miR-145
p27Kip 1 miRs 221/222
SOCS4 miR-25
Sox17 miR-595
Pdcd4 miR-21 miR-183
ZEB1 and ZEB2 miR-200 family
LOX miR-29a miR-30a
SLC7A5, ADAM9, LRP6,
CXCR4 miR-126
EGFR, CXCL 12 miR-137
MRTF-A miR-206
Rac1 miR-101
SphK2 miR-613
CARMA 1 miR-539
TUSC2, Rock1 miR-584
YAP1, SLC16a2, ERBB2 miR-375
VEGF-A miR-205 miR-126
p85b miR-126
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8.2. lncRNAs
More recently, many lncRNAs (>200 nt or even several kb in length) have been described to be
upregulated or downregulated in thyroid cancer tissues or cancer cell lines. Predicting miRNA/target
duplex [138] is used to detect miRNA/lncRNA interaction [139].
They are expressed in a tissue-specific manner and involved in tumorigenesis acting through
distinct molecular mechanisms on epigenetic modifications, transcriptional, and post-transcriptional
processing. In this way, they are implicated in cell cycle, cell differentiation, proliferation, apoptosis,
migration, and invasion [120,140]. However, the role and molecular mechanism that they play in
thyroid cancer, compared to other malignancies, remains largely unclear. Their involvement in cancer
pathogenesis and availability make lncRNAs ideal biomarkers for cancer prognosis and diagnosis.
Just as an example, we will discuss the importance of three relevant lncRNAs in thyroid cancer such
as H19, MALAT1, PTCSC3, among many others whose descriptions and their possible mechanism in
thyroid cancer, known to date, are summarized in Table 4.
8.2.1. H19
H19 is a typical lncRNA that is associated with various cancer types, with both tumor promoter
and suppressive functions [141]. Its expression is higher in thyroid tumor tissues, where enhance
proliferation and migration, comparing with normal thyroid cells [142].
8.2.2. Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1)
MALAT1 is a prooncogenic lncRNA in several cancer types [143]. Regarding thyroid cancer,
MALAT1 is highly expressed in PTC than in FTC and ATC [144]. In addition, MALAT1 expression is
higher in MTC than in normal thyroid [145].
8.2.3. Papillary Thyroid Carcinoma Susceptibility Candidate 3 (PTCSC3)
PTCSC3 is a lncRNA whose expression is strictly thyroid-specific and is downregulated either
in thyroid tumor tissues and in thyroid cell lines. When PTCSC3 acts as a tumor suppressor is a
competing endogenous RNA for miR-574–5p [146].
Table 4. LncRNAs associated with thyroid cancer (TC).
lncRNA Role in Thyroid Cancer References
RP5-1024C24.1 Associates negatively with late clinical stages [147]
CASC2 Expression correlates with multifocality and TNM [148]
PANDAR Inhibits proliferation, cell cycle and promote apoptosis [149]
ENSG00000235070.3 Correlates directly to BRAF (V600E) [150]
ENSG00000255020.1
GAS8-AS1
Suppresses cell proliferation in thyroid cancer [151]
Low Expression negatively correlates with LNM [152]
NONHSAG051968 Correlates negatively with tumor size
[153]NONHSAG018271 Suppresses tumor cell growth
NONHSAG007951
LINC00271 Involves in extrathyroidal invasion, LNM, advanced tumor stage and recurrence in TC [154]
LINC00663 Its role in cancer formation needs further investigation [155]
NONHSAT037832 Plays role in LNM and determines tumor size [156]
MEG3 Inhibits invasion and associates with LNM [157]
PTCSC2 Predisposes genetically to thyroid cancer [158]
PTCSC3 Suppresses cell growth and invasion [159,160]
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Table 4. Cont.
lncRNA Role in Thyroid Cancer References
PTCSC1 A candidate susceptibility gene for PTC [161]
NAMA Targets MAPK signaling pathway [162,163]
NONHSAT076754 Correlates to LNM in PTC [164]
n340790 Accelerates TC cell growth, motility and inhibit apoptosis [165]
HOTAIR
Triggers cell growth and invasion [166]
Associates with poor survival of TC patients [167]
NEAT1 Promotes tumor progression and tumor size [168]
ENSG00000273132.1 Overexpression correlates directly to BRAF (V600E) [150]
ENSG00000230498.1 Overexpression correlates directly to BRAF (V600E)
CTD-3193013 A node of co-regulation with other lncRNAs and tumor size
[147]AC007255.8 Correlates to clinical stage (patient age)
HOXD-AS1 Correlates to clinical stage
RP11-40216.1 Expression proportional to LNM
HIT000218960 Correlates to TNM stage, LNM, and multifocality [169]
MALAT1 Regulates proliferation, migration and EMT via TGF-β [144]
NR_036575.1 Promotes proliferation and migration of thyroid cancer [170]
ANRIL Proliferation, invasion and metastasis via TGF-β/Smad [171]
XLOC_051122 Oncogenic with metastatic potentials [172]
XLOC_006074 Oncogenic with metastatic potentials and prognostic role
LOC100507661 Enhances proliferation, migration and invasion [173]
H19 Increases proliferation, migration and invasion [142]
FAL1 Associates positively with risk of multifocality [174]
ENST00000537266 Promotes proliferation and inhibit apoptosis [175]
ENST00000426615 Regulates proliferation, migration, apoptosis and cell cycle
PVT1 Increases thyroid cancer cell proliferation [176]
BANCR Enhances thyroid cancer cell proliferation and inhibits apoptosis [163,177]
FOXD2-AS1 Contribute to proliferation, migration and invasion of cancer cells, and its deregulation is related tocarcinogenesis, overall survival, disease free survival, prognosis and tumor progression [178]
AFAP1-AS1
The dysregulated expression of AFAP1-AS1 is related to carcinogenesis, overall survival,
disease-free survival, progression-free survival and tumor progression containing lymph node
metastasis, distant metastasis, histological grade, tumor size and tumor stage
[179]
ENST00000489676 It influences PTC cell proliferation and invasion through regulating miR-922 [180]
LUCAT1
The overexpression of LUCAT1 is related to PTC development, through acting in cell-cycle
regulation, proliferation, epigenetic modifications through LUCAT1/ CDK1/ EZH2/ P57/ P21/
HDAC1/ DNMT1/ P53/ BAX axis and apoptosis, via extrinsic pathway activating caspases
[181]
Notes: LNM, lymph node metastasis; N/A, data not available; TNM, tumor node metastasis.
8.3. circRNAs
circRNAs were identified in human papillary thyroid cancer [182] and lately associated with
different cancers [183–185]. There are four types: exonic circRNAs, circular RNAs from introns,
exon–intron circRNAs, and intergenic circRNAs [186]. They are expressed in thousands of human
genes and they have been suggested to modify gene expression through sponging miRNAs and interact
with RNA-binding proteins, and they can also be positive regulators of their parental genes [187–189].
All circRNAs linked to thyroid cancer known to date have been compiled in Table 5.
This is a very recent field of study in thyroid cancer and then, most of the circRNAs included
in Table 5 are exclusively associated with this type of tumor, at least until today. Further studies
are required to decipher if they are involved in the develop of some other tumors. However, four
circRNAs have already been found in other cancers: circZFR, circ-ITCH, hsa_circ_0004458 and
hsa_circRNA_100395.
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Table 5. CircRNAs described on thyroid cancer.
circRNA Role in Thyroid Cancer Reference
circMAN1A2 Upregulated [190]
circRAPGEF5 Upregulated; it acts through miR-198/FGFR1 [191]
circ_0067934
Upregulated; it improves the development of thyroid
carcinoma by promoting EMT and PI3K/AKT
signaling pathways
[192]
circ_0025033 Upregulated; it promotes PTC cell proliferation and invasionvia sponging miR-1231 and miR-1304 [193]
Hsa_circ_0008274 Upregulated; it promotes cell proliferation and invasioninvolving AMPK/mTOR signaling pathway in PTC [194]
circZFR Regulating miR-3619-5p/CTNNB1 axis and activatingWnt/β-catenin pathway. [195]
circRNA_102171
Upregulated; it promotes PTC progression through
activating Wnt/β-catenin pathway in a
CTNNBIP1-dependent way
[196]
circNUP214 Oncogenic role in PTC by acting as a sponge for miR-145,leading to upregulation of ZEB2 [197]
circ-ITCH Upregulated; it suppresses papillary thyroid cancerprogression through miR-22-3p/CBL/β-catenin pathway [198]
hsa_circ_0004458 Promoted the progression of PTC through inhibition ofmiR-885-5p and activation of RAC1 [199]
chr5: 160757890-160763776-, chr12: 40696591-40697936+,
chr7: 22330794-22357656-, chr21: 16386665-16415895-, chr7:
91924203-91957214+, chr2: 179514891-179516047-, chr9:
16435553-16437522-, and chr22: 36006931-36007153-
Up/downregulated [200]
circZFR Contributes to PTC cell proliferation and invasion bysponging miR-1261 and facilitating C8orf4 expression [201]
hsa_circ_0137287 Downregulated in PTC tissues [202]
hsa_circRNA_100395 Downregulated; it is related with miR-141-3p/miR-200a-3paxis in PTC tumors [182]
hsa_circ_0058124 The hsa_circ_0058124/NOTCH3/GATAD2A axis is critical forPTC tumorigenesis and invasiveness [203]
9. Conclusions and Future Perspectives
Thyroid cancer is a disease induced by progressive genetic and epigenetic molecular abnormalities.
Most studies describe several classical aberrations involved in the tumorigenesis and progression of
this tumor, such as point mutations, gene copy number variations, and aberrant gene methylation.
Additionally, increasing evidence points to ncRNAs as important players in the regulation of a variety of
biological functions of thyroid cancer cells (RNA stability, epigenetic processes, chromatin accessibility,
translation, gene expression in mitochondria, anterograde and retrograde signaling, and intracellular
and intercellular signaling) [173,175,204]. However, only a few structures of lncRNA are known.
Furthermore, ncRNAs may be used for diagnosis, prognosis, and as potential therapeutic agents of
thyroid cancer.
The genetic landscape of thyroid cancer is growing rapidly. Therapies that are targeted at genetic
mutations related to this tumor are being used in patient care and clinical trials. In comparison with
traditional disease-specific trials, molecular allocation studies (“basket studies”) are testing targeted
therapies in patients whose tumors carry particular mutations, in spite of the tumor type or origin [205].
These studies are more informative on anticancer therapies because they include a greater number of
patients. Regarding thyroid cancers due to low prevalence mutations (i.e.: rearrangements of RET,
NTRK1, NTRK3, or ALK), they could be included in trials with selective kinase inhibitors with probed
efficacy in other types of cancer. Thus, targeted therapy in thyroid cancer has been mainly focused on
tyrosine kinase inhibitors. Furthermore, cancer adaptation to hypoxia and angiogenesis through the
transcription factor hypoxia-inducible factor 1-alpha has been found [4]. This factor is only present in
cancer tissues and therefore could be a precision medicine paradigm for further research focused on
drivers uniquely present in cancer tissues.
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Finally, the correlation of molecular profile (obtained by new sequencing technologies) with
clinicopathological characteristics will lead to the development of novel precision therapies, reducing
morbidity and mortality in thyroid cancer patients [206–208]. In this sense, differential response to a
mitogen-activated protein kinase inhibitor was found to be related to the thyroid cancer genotype [209].
Molecular testing of mutation hotspots, rearrangements, and gene expression is now an effective
diagnostic tool to better select patients for potential thyroid surgery [210,211].
The TCGA project mentioned in this review [20] shifts the focus regarding thyroid cancer
classification to a strong multidimensional genomic and integrative approach, which has relevant
consequences on basic pathobiology, tumor classification, and therapies. In this manner, thyroid cancer
therapy would enter the realm of precision medicine, which will favor a more personalized approach
to this pathology, achieving, ultimately, greater hope and quality of life for patients.
In summary, the diagnosis and treatment of thyroid cancer is nowadays influenced by the
molecular characterization of thyroid cancer types. The improvement of such techniques would help
to reduce unnecessary treatments in indolent thyroid cancers, as well as improve the outcomes in
patients with clinically aggressive cancers.
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